Altre lingue Cue Biopharma, Inc.

Azioni

CUE

US22978P1066

Tempo differito Nasdaq Altri mercati azionari 15:56:49 19/04/2024			Variaz. 5gg	Var. 1 gen.
1,599 ^USD	+1,22%		-8,62%	-39,42%

08/04	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
28/03	Cue Biopharma, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Cue Biopharma to Host Business Update Call and Webcast	02/04
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
North American Morning Briefing : Investors -2-	18/03
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	29/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23/11
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	22/11
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	09/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma to Host Business Update Call and Webcast	02/11
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	27/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cue Biopharma, Inc.

Azioni

CUE

US22978P1066

Altre lingue

Filtri